Free tool
FAERS Monitor: Claritin Hives Relief
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020641 or its brand name (Claritin Hives Relief, Loratadine). Reports on generic versions are filed under their own applications.
Reports
104,422
Serious
49,251
47% of reports
Hospitalization
22,962
Death reported
4,538
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective12,282
- fatigue6,606
- nausea5,803
- headache5,316
- dyspnoea4,803
- diarrhoea4,797
- off label use4,595
- dizziness4,298
- pain4,057
- rash3,383
- pruritus3,361
- cough3,106
- vomiting2,966
- arthralgia2,894
- somnolence2,867
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 965 |
| 2005 | 1,071 |
| 2006 | 1,067 |
| 2007 | 939 |
| 2008 | 1,073 |
| 2009 | 1,316 |
| 2010 | 1,637 |
| 2011 | 2,020 |
| 2012 | 3,016 |
| 2013 | 3,961 |
| 2014 | 4,684 |
| 2015 | 7,326 |
| 2016 | 9,310 |
| 2017 | 8,781 |
| 2018 | 7,750 |
| 2019 | 7,823 |
| 2020 | 7,027 |
| 2021 | 6,322 |
| 2022 | 6,132 |
| 2023 | 5,526 |
| 2024 | 6,045 |
| 2025 | 5,986 |
| 2026 | 4,644 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,949,737 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 2,867 | 2.9 | 2.8 | 3,537 |
| coughSignal | 3,106 | 2.2 | 2.2 | 2,147 |
| drug ineffective | 12,282 | 1.9 | 1.9 | 5,396 |
| pruritus | 3,361 | 1.8 | 1.7 | 1,132 |
| dizziness | 4,298 | 1.7 | 1.7 | 1,379 |
| fatigue | 6,606 | 1.7 | 1.7 | 2,027 |
| dyspnoea | 4,803 | 1.7 | 1.7 | 1,458 |
| headache | 5,316 | 1.7 | 1.7 | 1,615 |
| rash | 3,383 | 1.6 | 1.5 | 704 |
| diarrhoea | 4,797 | 1.5 | 1.5 | 820 |
| nausea | 5,803 | 1.5 | 1.4 | 933 |
| arthralgia | 2,894 | 1.4 | 1.4 | 342 |
| pain | 4,057 | 1.3 | 1.3 | 344 |
| vomiting | 2,966 | 1.3 | 1.2 | 175 |
| off label use | 4,595 | 1.1 | 1.0 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.